Prestige Consumer Healthcare
Builds and markets an acquisition-led portfolio of OTC health and personal-care brands.
Something off on this page? Send us feedback.
Profile
Develops and markets acquired OTC health and personal-care brands spanning better breathing, women’s health, eye care, digestive care, pain relief, and therapeutic skin care. North America drives most sales, while international exposure is expanding through Breathe Right and Australia-based LaCorium.
Develops, markets, and distributes over-the-counter health and personal-care brands across better breathing, women’s health, eye and ear care, digestive care, pain relief, oral care, dermatology, pediatric care, and sleep. Breathe Right, now its largest brand, joins Monistat, Summer’s Eve, Clear Eyes, TheraTears, Dramamine, Fleet, and DenTek; the LaCorium acquisition adds Dermal Therapy in Australian therapeutic skin care.
Runs an acquisition-led model that pairs established brands with advertising, product extensions, and broad retail distribution. North America supplies most revenue, while Australia, Europe, and other international markets form a smaller but expanded footprint.
Operates through North American OTC Healthcare and International OTC Healthcare. Production is mostly outsourced, sales are concentrated among major retail and e-commerce customers, and products are governed by FDA and foreign regulations.
Company facts
Key statistics
Year to date −14.3% · Average volume (30d) 524.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 14, 2026 | Oppenheimer | Downgrade | Outperform | Perform | ||
| Jan 30, 2026 | Jefferies | Target | $71 | $66 | ||
| Oct 27, 2025 | Jefferies | Reiterate | Hold | $71 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q1 FY27 | $0.89 | $0.98 | +9.6% | $253.0M | $265.7M | +5.0% | +2.74% |
| May 13, 2026Q4 FY26 | $1.39 | $1.23 | −11.5% | $293.6M | $281.6M | −4.1% | −11.35% |
| Feb 5, 2026Q3 FY26 | $1.16 | $1.14 | −1.7% | $282.2M | $283.4M | +0.4% | +1.19% |
| Nov 6, 2025Q2 FY26 | $0.97 | $1.07 | +10.3% | $294.2M | $274.1M | −6.8% | −2.30% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $296.8M | $249.5M | $274.1M | $283.4M | $281.6M | $265.7M | |
| Gross profit | $175.7M | $135.1M | $154.1M | $157.4M | $140.9M | $136.2M | |
| Operating income | $88.4M | $71.8M | $79.7M | $82.5M | $75.5M | $52.5M | |
| Net income | $50.1M | $47.5M | $42.2M | $46.7M | $53.9M | $29.2M | |
| Diluted EPS | $1.00 | $0.95 | $0.86 | $0.97 | $1.13 | $0.61 | |
| Gross margin | 59.2% | 54.2% | 56.2% | 55.5% | 50.0% | 51.3% | |
| Operating margin | 29.8% | 28.8% | 29.1% | 29.1% | 26.8% | 19.8% |
Fiscal years (4-quarter sums)FY22 $1.09B · FY23 $1.13B · FY24 $1.13B · FY25 $1.14B · FY26 $1.09B
Revenue by product · Q1 FY27
Revenue by geography · FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $89.1M · Total debt $2.06B · Total assets $4.57B · Shareholders' equity $1.92B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 47.37M · Float 46.70M · 98.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.83M | 16.53% | 13F | Aug 7, 2026 |
| Ariel Investments, LLC | 4.87M | 10.28% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 2.83M | 5.96% | 13F | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 2.66M | 5.62% | 13F | Aug 11, 2026 |
| Fuller & Thaler Asset Management, Inc. | 2.33M | 4.92% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 11, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −351 | $52.28 |
| May 7, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −305 | $54.36 |
| May 5, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −1,553 | $55.06 |
| Feb 11, 2026 | Jeffrey Zerillo | officer: Senior VP Operations | −1,000 | $65.93 |
| Dec 1, 2025 | Jeffrey Zerillo | officer: Senior VP Operations | −281 | $60.00 |
Peers
- Haleon (ADR)
Broad consumer-health pure play across oral, pain, respiratory, and GI
- Kenvue
Consumer-health pure play spanning OTC self care, eye, oral, and baby care
- Perrigo
Store-brand and self-care OTC rival across retailer shelves
- Church & Dwight
Oral, cold-remedy, women's-health, and personal-care brand overlap
- Procter & Gamble
Scale competitor in personal health, oral care, and feminine care
- Alcon
Focused eye-care competitor against drops and ocular-health brands
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare | $52.47 | +0.01% | $2.49B | 14.7 | 11.2 | 2.2 | +6.5% |
| Haleon (ADR) | $10.11 | +0.05% | $44.52B | 20.7 | 10.8 | 2.9 | +3.7% |
| Kenvue | $19.17 | +0.03% | $36.81B | 22.0 | 16.0 | 2.4 | +3.0% |
| Perrigo | $14.44 | −0.35% | $2.00B | — | 6.1 | 0.5 | −3.2% |
| Church & Dwight | $101.26 | +0.03% | $23.99B | 32.7 | 25.9 | 3.9 | +1.6% |
| Procter & Gamble | $143.75 | +0.01% | $341.75B | 21.7 | 20.5 | 3.9 | +1.5% |
| Alcon | $72.15 | +0.21% | $35.12B | 55.4 | 18.6 | 3.3 | +7.5% |
| Median | 22.0 | 17.3 | 3.1 | +2.3% |